Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Manual therapies in cystic fibrosis care: a scoping review
    Sinderholm, Niklas Sposato
    Bjersa, Kristofer
    CHIROPRACTIC & MANUAL THERAPIES, 2023, 31 (01)
  • [42] Home Intravenous Antibiotic Protocols for Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis: A Scoping Review
    Odendaal, Michelle
    Tilbury, Zak
    Conway, Aaron
    HOME HEALTH CARE MANAGEMENT AND PRACTICE, 2025,
  • [43] A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis
    Ilene L. Hollin
    Karen A. Robinson
    Applied Health Economics and Health Policy, 2016, 14 : 151 - 159
  • [44] A Scoping Review of Healthcare Costs for Patients with Cystic Fibrosis
    Hollin, Ilene L.
    Robinson, Karen A.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2016, 14 (02) : 151 - 159
  • [45] THE SAFETY AND EFFICACY OF INHALED MEROPENEM FOR ACUTE PULMONARY EXACERBATION IN CYSTIC FIBROSIS
    Brackett, M.
    Liveris, M.
    Stanczak, N.
    Boas, S.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 314 - 314
  • [46] Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis
    Kapur, Nitin
    Masters, Ian B.
    Morris, Peter S.
    Galligan, John
    Ware, Robert
    Chang, Anne B.
    PEDIATRIC PULMONOLOGY, 2012, 47 (01) : 68 - 75
  • [47] Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past
    Liu, Yang
    He, Kang-Zhe
    Xu, Jin-Fu
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64 (04)
  • [48] TREATMENT WITH OFLOXACIN OF PULMONARY EXACERBATION OF CYSTIC-FIBROSIS IN CHILDREN AND JUVENILES
    BOWING, B
    BERTHOLD, M
    MEDIZINISCHE WELT, 1994, 45 (10): : 438 - 439
  • [49] The role of procalcitonin as a biomarker for acute pulmonary exacerbation in subjects with cystic fibrosis and non-cystic fibrosis bronchiectasis
    Mammadov, Firuz
    Olgun Yildizel, Sehnaz
    Kocakaya, Derya
    Arikan, Huseyin
    Cinar, Caner
    Eryuksel, Emel
    Ceyhan, Berrin
    MARMARA MEDICAL JOURNAL, 2022, 35 (02): : 164 - 171
  • [50] A novel neutrophil derived inflammatory biomarker of pulmonary exacerbation in cystic fibrosis
    Reeves, Emer P.
    Bergin, David A.
    Fitzgerald, Sean
    Hayes, Elaine
    Keenan, Joanne
    Henry, Michael
    Meleady, Paula
    Vega-Carrascal, Isabel
    Murray, Michelle A.
    Low, Teck Boon
    McCarthy, Cormac
    O'Brien, Emmet
    Clynes, Martin
    Gunaratnam, Cedric
    McElvaney, Noel G.
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (02) : 100 - 107